|
所属 |
医学部 附属病院 消化器内科 |
|
職名 |
助教 |
|
外部リンク |
|
論文 【 表示 ／ 非表示 】
-
Ozono Y., Shide K., Kameda T., Kamiunten A., Tahira Y., Sekine M., Akizuki K., Nakamura K., Iwakiri H., Sueta M., Hidaka T., Kubuki Y., Yamamoto S., Hasuike S., Sawaguchi A., Nagata K., Shimoda K.
Leukemia 35 ( 2 ) 454 - 467 2021年2月
担当区分：筆頭著者 記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Leukemia
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by clonal myeloproliferation, progressive bone marrow (BM) fibrosis, splenomegaly, and anemia. BM fibrosis was previously thought to be a reactive phenomenon induced by mesenchymal stromal cells that are stimulated by the overproduction of cytokines such as transforming growth factor (TGF)-β1. However, the involvement of neoplastic fibrocytes in BM fibrosis was recently reported. In this study, we showed that the vast majority of collagen- and fibronectin-producing cells in the BM and spleens of Jak2V617F-induced myelofibrosis (MF) mice were fibrocytes derived from neoplastic hematopoietic cells. Neoplastic monocyte depletion eliminated collagen- and fibronectin-producing fibrocytes in BM and spleen, and ameliorated most characteristic MF features in Jak2V617F transgenic mice, including BM fibrosis, anemia, and splenomegaly, while had little effect on the elevated numbers of megakaryocytes and stem cells in BM, and leukothrombocytosis in peripheral blood. TGF-β1, which was produced by hematopoietic cells including fibrocytes, promoted the differentiation of neoplastic monocytes to fibrocytes, and elevated plasma TGF-β1 levels were normalized by monocyte depletion. Collectively, our data suggest that neoplastic fibrocytes are the major contributor to BM fibrosis in PMF, and TGF-β1 is required for their differentiation.
-
Ozono Y., Nagata K., Hasuike S., Iwakiri H., Nakamura K., Tsuchimochi M., Yamada Y., Takaishi Y., Sueta M., Miike T., Tahara Y., Yamamoto S., Shide K., Hidaka T., Kubuki Y., Kusumoto K., Ochiai T., Kato J., Komada N., Hirono S., Kuroki K., Shigehira M., Shimoda K.
World Journal of Hepatology 9 ( 36 ) 1340 - 1345 2017年12月
担当区分：筆頭著者 記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：World Journal of Hepatology
AIM To evaluate the efficacy and safety of a regimen containing sofosbuvir (SOF) and ledipasvir (LDV) in Japanese patients aged ≥ 75 years with hepatitis C genotype 1. METHODS This multicenter, retrospective study consisted of 246 Japanese patients with HCV genotype 1 at nine centers in Miyazaki prefecture in Japan. Demographic, clinical, virological, and adverse effects (AE)-related data obtained during and after SOF/LDV therapy were collected from medical records. These patients were divided into two groups, younger (aged < 75 years) and elderly (aged ≥ 75 years). Virological data and AEs were analyzed by age group. RESULTS The sustained virological response (SVR) rates at 12 wk after treatment were 99.2%, 99.4%, and 98.7% in the overall population and in patients aged < 75 and ≥ 75 years, respectively. Common AEs during therapy were headache, pruritus, constipation, and insomnia. These occurred in fewer than 10% of patients, and their incidence was not significantly different between the younger and elderly groups. Two patients discontinued treatment, one due to a skin eruption and the other due to cerebral bleeding. CONCLUSION Compared with younger patients, elderly patients had a similar virological response and tolerance to SOF/LDV therapy.
-
Liver abscess in advanced hepatocellular carcinoma after atezolizumab plus bevacizumab treatment: A case report. 査読あり
Uchida K, Ozono Y, Uchiyama N, Hatada H, Nakamura K, Komaki Y, Iwakiri H, Hasuike S, Nagata K, Sato Y, Kawakami H
Medicine 101 ( 35 ) e30486 2022年9月
-
特集 胆道ドレナージのすべて-適応･方法 2.各論(7)経皮的胆囊ドレナージ
河上 洋, 畑田 紘志, 内山 尚美, 小川 宗一郎, 田村 穂高, 大園 芳範
臨床消化器内科 37 ( 10 ) 1342 - 1349 2022年8月
-
Hematochezia Due to Panitumumab-induced Colitis with Vitamin K Deficiency. 査読あり
Tamura H, Nakashima K, Uchiyama N, Ogawa S, Hatada H, Yoshida N, Uchida K, Ozono Y, Tanaka H, Yamamto K, Kawakami H
Internal medicine (Tokyo, Japan) 61 ( 10 ) 1503 - 1509 2022年5月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：一般社団法人 日本内科学会
Panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, has been shown to be useful in treating either advanced or recurrent KRAS/NRAS/BRAF wild-type colorectal cancer. We herein report the case of a 60-year-old man with short bowel syndrome who developed hematochezia due to panitumumab-induced colitis with vitamin K deficiency during third-line chemotherapy. The cause of vitamin K deficiency was the lack of intravenous vitamin K supplementation following a change from central venous nutrition to peripheral venous nutrition. We advise clinicians to carefully check for colitis and manage the infusions of chemotherapy patients with short bowel syndrome.
科研費（文科省・学振・厚労省）獲得実績 【 表示 ／ 非表示 】
-
肝硬変、NASH発症・進展に果たす造血細胞の関与の解明と新たな治療標的の確立
研究課題/領域番号：19K17404 2019年04月 - 2022年03月
科学研究費補助金 若手研究
担当区分：研究代表者